NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH) LONDON, Dec. 20, 2024 (GLOBE...
Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia familiar homocigótica (HFho) Evkeeza es un medicamento...
Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia...
Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH) For the...
Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare omozigote (HoFH) Evkeeza è un farmaco, primo nel...
Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein Evkeeza® ist das erste von der U.S. Food and Drug...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.6 | -3.80952380952 | 42 | 42.2 | 40.2 | 206 | 41.29294404 | DE |
4 | -4.2 | -9.41704035874 | 44.6 | 46.4 | 40.2 | 261 | 42.0995687 | DE |
12 | -10.1 | -20 | 50.5 | 53.5 | 40.2 | 126 | 44.27703085 | DE |
26 | 2.8 | 7.44680851064 | 37.6 | 54 | 37.2 | 151 | 45.38101378 | DE |
52 | -2.6 | -6.04651162791 | 43 | 54 | 34.799999 | 169 | 42.96720088 | DE |
156 | 1.8 | 4.66321243523 | 38.6 | 54 | 30.6 | 164 | 41.72689478 | DE |
260 | 1.8 | 4.66321243523 | 38.6 | 54 | 30.6 | 164 | 41.72689478 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.